CL2016000724A1 - Acido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acetico para su uso e n la prevencion o el tratamiento de la lesion renal aguda. - Google Patents

Acido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acetico para su uso e n la prevencion o el tratamiento de la lesion renal aguda.

Info

Publication number
CL2016000724A1
CL2016000724A1 CL2016000724A CL2016000724A CL2016000724A1 CL 2016000724 A1 CL2016000724 A1 CL 2016000724A1 CL 2016000724 A CL2016000724 A CL 2016000724A CL 2016000724 A CL2016000724 A CL 2016000724A CL 2016000724 A1 CL2016000724 A1 CL 2016000724A1
Authority
CL
Chile
Prior art keywords
phenoxy
oxazolo
dimethyl
prevention
treatment
Prior art date
Application number
CL2016000724A
Other languages
English (en)
Inventor
Dieter Kadereit
Matthias Schaefer
Thomas Huebschle
Philip Janiak
Véronique Briand
Sabine Gratzer
Ashfaq Parkar
Bruno Poirier
Paulus Wohlfart
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49488539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000724(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2016000724A1 publication Critical patent/CL2016000724A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ACIDO {4-[5-(3-CLORO-FENOXI)-OXAZOLO[5,4-D]PIRIMIDIN-2-IL]-2,6-DIMETIL-FENOXI}-ACETICO O UNA SAL DEL MISMO PARA SU USO EN LA PREVENCION O EL TRATAMIENTO DE LA LESION RENAL AGUDA; MEDICAMENTO Y COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y ARTICULO MANUFACTURADO QUE COMPRENDE A DICHA COMPOSICION.
CL2016000724A 2013-10-15 2016-03-29 Acido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acetico para su uso e n la prevencion o el tratamiento de la lesion renal aguda. CL2016000724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20130306417 EP2862574A1 (en) 2013-10-15 2013-10-15 {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

Publications (1)

Publication Number Publication Date
CL2016000724A1 true CL2016000724A1 (es) 2016-09-23

Family

ID=49488539

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000724A CL2016000724A1 (es) 2013-10-15 2016-03-29 Acido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acetico para su uso e n la prevencion o el tratamiento de la lesion renal aguda.

Country Status (24)

Country Link
US (1) US9782411B2 (es)
EP (2) EP2862574A1 (es)
JP (1) JP6458016B2 (es)
KR (1) KR102348608B1 (es)
CN (1) CN105658220B (es)
AR (1) AR098028A1 (es)
AU (1) AU2014336254B9 (es)
BR (1) BR112016007669B1 (es)
CA (1) CA2926211C (es)
CL (1) CL2016000724A1 (es)
CR (1) CR20160172A (es)
DK (1) DK3057591T3 (es)
EA (1) EA032012B1 (es)
ES (1) ES2898403T3 (es)
HK (1) HK1225611A1 (es)
IL (2) IL244686B (es)
MA (1) MA39032B2 (es)
MX (1) MX2016004778A (es)
PH (1) PH12016500563A1 (es)
PT (1) PT3057591T (es)
SG (1) SG11201602263TA (es)
TN (1) TN2016000110A1 (es)
TW (1) TWI685340B (es)
WO (1) WO2015055694A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019003949A (es) * 2016-10-05 2019-06-10 Mitobridge Inc Metodos para tratar lesion renal aguda.
CN106905348B (zh) * 2017-02-13 2018-12-04 牡丹江医学院 一种预防和治疗急性肾损伤的药物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10033353A1 (de) 2000-07-08 2002-01-24 Aventis Pharma Gmbh Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
RU2379299C2 (ru) 2003-11-21 2010-01-20 Актелион Фармасьютиклз Лтд Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов
CN102791717B (zh) * 2010-01-14 2016-03-30 赛诺菲 具有2,5-取代的噁唑并嘧啶环的羧酸衍生物

Also Published As

Publication number Publication date
AU2014336254B9 (en) 2020-02-20
EP3057591A1 (en) 2016-08-24
CA2926211C (en) 2022-03-29
EP3057591B1 (en) 2021-09-08
CR20160172A (es) 2016-06-08
AU2014336254B2 (en) 2020-02-06
SG11201602263TA (en) 2016-04-28
DK3057591T3 (da) 2021-12-13
IL244686B (en) 2021-04-29
CA2926211A1 (en) 2015-04-23
TN2016000110A1 (en) 2017-07-05
ES2898403T3 (es) 2022-03-07
NZ719089A (en) 2020-09-25
PH12016500563A1 (en) 2016-05-23
EA032012B1 (ru) 2019-03-29
CN105658220A (zh) 2016-06-08
EA201690762A1 (ru) 2016-07-29
EP2862574A1 (en) 2015-04-22
JP2016534986A (ja) 2016-11-10
JP6458016B2 (ja) 2019-01-23
KR20160060759A (ko) 2016-05-30
MX2016004778A (es) 2017-01-11
IL244686A0 (en) 2016-04-21
WO2015055694A1 (en) 2015-04-23
BR112016007669B1 (pt) 2023-01-10
MA39032B2 (fr) 2020-10-28
CN105658220B (zh) 2019-04-19
KR102348608B1 (ko) 2022-01-06
AR098028A1 (es) 2016-04-27
TW201605453A (zh) 2016-02-16
US9782411B2 (en) 2017-10-10
IL282097A (en) 2021-05-31
HK1225611A1 (zh) 2017-09-15
US20160235756A1 (en) 2016-08-18
BR112016007669A2 (pt) 2017-08-01
PT3057591T (pt) 2021-12-09
MA39032A1 (fr) 2017-04-28
TWI685340B (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
CL2015003442A1 (es) Derivados heterociclicos
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2014002880A1 (es) Compuestos derivados de heterociclos nitrogenados o sus sales, inhibidores selectivos de la pde2a; medicamento que los comprende; y su uso para la profilaxis y tratamiento de la esquizofrenia.
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CL2012002437A1 (es) Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos.
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
CL2013002193A1 (es) Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno.
IL282097A (en) {4-[5-(3-chloro-phenoxy)-(oxazolo[5,4-D]pyrimidin-2-yl]-2, 6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of severe kidney damage